Technical Analysis for NVO - Novo Nordisk A/S
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bullish Setup | Bullish Swing Setup | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Three Weeks Tight | Range Contraction | 1.88% | |
| Outside Day | Range Expansion | 1.88% | |
| Inside Day | Range Contraction | 0.64% | |
| Slingshot Bullish | Bullish Swing Setup | 1.22% | |
| Gapped Down | Weakness | 1.22% | |
| New 52 Week Closing High | Bullish | -1.01% | |
| Expansion Breakout | Bullish Swing Setup | -1.01% | |
| Pocket Pivot | Bullish Swing Setup | -1.01% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 9 hours ago |
| Up 2% | about 9 hours ago |
| Up 1 ATR | about 9 hours ago |
| 60 Minute Opening Range Breakout | about 9 hours ago |
| Gap Up Partially Closed | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/07/2024
Novo Nordisk A/S Description
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Life Sciences Diabetes IBD 50 Pharmaceutical Products Inflammation Obesity Insulin Endocrine System Hormones Peptide Hormones Growth Hormone Glucagon Like Peptide 1 Diabetes Care Growth Hormone Therapy Hormone Therapy Pharmaceuticals Segment Anti Diabetic Drugs Haemophilia Related Delivery Systems
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 148.15 |
| 52 Week Low | 46.5309 |
| Average Volume | 3,596,839 |
| 200-Day Moving Average | 114.90 |
| 50-Day Moving Average | 134.82 |
| 20-Day Moving Average | 142.26 |
| 10-Day Moving Average | 142.96 |
| Average True Range | 2.68 |
| RSI (14) | 62.83 |
| ADX | 35.06 |
| +DI | 30.59 |
| -DI | 15.11 |
| Chandelier Exit (Long, 3 ATRs) | 140.10 |
| Chandelier Exit (Short, 3 ATRs) | 140.83 |
| Upper Bollinger Bands | 146.75 |
| Lower Bollinger Band | 137.76 |
| Percent B (%b) | 0.85 |
| BandWidth | 6.32 |
| MACD Line | 2.65 |
| MACD Signal Line | 2.81 |
| MACD Histogram | -0.157 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 149.07 | ||||
| Resistance 3 (R3) | 148.85 | 147.42 | 148.46 | ||
| Resistance 2 (R2) | 147.42 | 146.49 | 147.53 | 148.25 | |
| Resistance 1 (R1) | 146.42 | 145.92 | 146.92 | 146.64 | 148.05 |
| Pivot Point | 144.99 | 144.99 | 145.24 | 145.10 | 144.99 |
| Support 1 (S1) | 143.99 | 144.06 | 144.49 | 144.21 | 142.79 |
| Support 2 (S2) | 142.56 | 143.49 | 142.67 | 142.59 | |
| Support 3 (S3) | 141.56 | 142.56 | 142.38 | ||
| Support 4 (S4) | 141.78 |
